These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 344042)

  • 21. Bromocriptine combined with levodopa in Parkinson's disease.
    Gauthier G; Martins da Silva A
    Eur Neurol; 1982; 21(4):217-26. PubMed ID: 7117308
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bromocriptine in the treatment of Parkinson's disease: a double-blind study against L-dopa/carbidopa.
    Gawel M; Riopelle R; Libman I; Bouchard S
    Adv Neurol; 1987; 45():535-8. PubMed ID: 3548263
    [No Abstract]   [Full Text] [Related]  

  • 23. Low dosages of bromocriptine added to levodopa in Parkinson's disease.
    Hoehn MM; Elton RL
    Neurology; 1985 Feb; 35(2):199-206. PubMed ID: 3969207
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A double-blind trial of bromocriptine in Parkinson's disease.
    Mackenzie RA; Lance JW
    Med J Aust; 1978 Nov; 2(3 Suppl):27-8. PubMed ID: 370527
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of the on-off syndrome in Parkinsonism with low dose bromocriptine in combination with levodopa.
    Bateman DN; Coxon A; Legg NJ; Reid JL
    J Neurol Neurosurg Psychiatry; 1978 Dec; 41(12):1109-13. PubMed ID: 366085
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A comparison of bromocriptine (Parlodel) and levodopa-carbidopa (Sinemet) for treatment of "de novo" Parkinson's disease patients.
    Libman I; Gawel MJ; Riopelle RJ; Bouchard S
    Can J Neurol Sci; 1987 Nov; 14(4):576-80. PubMed ID: 3319120
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ropinirole as an adjunct to levodopa in the treatment of Parkinson's disease: a 16-week bromocriptine controlled study.
    Im JH; Ha JH; Cho IS; Lee MC
    J Neurol; 2003 Jan; 250(1):90-6. PubMed ID: 12527999
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Early combination of bromocriptine and levodopa in Parkinson's disease: a prospective randomized study of two parallel groups over a total follow-up period of 44 months including an initial 8-month double-blind stage.
    Giménez-Roldán S; Tolosa E; Burguera JA; Chacón J; Liaño H; Forcadell F
    Clin Neuropharmacol; 1997 Feb; 20(1):67-76. PubMed ID: 9037575
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A six-month multicentre, double-blind, bromocriptine-controlled study of the safety and efficacy of ropinirole in the treatment of patients with Parkinson's disease not optimally controlled by L-dopa.
    Brunt ER; Brooks DJ; Korczyn AD; Montastruc JL; Stocchi F;
    J Neural Transm (Vienna); 2002 Apr; 109(4):489-502. PubMed ID: 11956968
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bromocriptine in Parkinson disease.
    Lieberman AN; Goldstein M
    Pharmacol Rev; 1985 Jun; 37(2):217-27. PubMed ID: 3901046
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bromocriptine in the management of end of dose deterioration in Parkinson's disease.
    Grimes JD; King DB; Kofman OS; Molina-Negro P; Wilson AF; Bouchard S
    Can J Neurol Sci; 1984 Nov; 11(4):452-6. PubMed ID: 6518428
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dopaminergic agonists in Parkinsonism.
    Claveria LE; Teychenne PF; Calne DB; Petrie A; Bassendine MF
    Adv Neurol; 1975; 9():383-92. PubMed ID: 1096576
    [No Abstract]   [Full Text] [Related]  

  • 33. Bromocriptine in Parkinsonism.
    Pearce I; Pearce JM
    Br Med J; 1978 May; 1(6124):1402-4. PubMed ID: 348261
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Parkinson-Control study: a 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease.
    Castro-Caldas A; Delwaide P; Jost W; Merello M; Williams A; Lamberti P; Aguilar M; Del Signore S; Cesaro P;
    Mov Disord; 2006 Apr; 21(4):500-9. PubMed ID: 16267842
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Primary combination therapy of early Parkinson's disease. A long-term comparison between the combined regimen bromocriptine/levodopa and levodopa monotherapy--first interim report.
    Przuntek H; Welzel D; Schwarzmann D; Letzel H; Kraus PH
    Eur Neurol; 1992; 32 Suppl 1():36-45. PubMed ID: 1425819
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Third interim report of the nationwide collaborative study on the long-term effects of bromocriptine in the treatment of parkinsonian patients.
    Nakanishi T; Kanazawa I; Goto I; Iwata M; Kowa H; Mannen T; Mizuno Y; Nishitani H; Ogawa N; Takahashi A
    Eur Neurol; 1990; 30 Suppl 1():3-8. PubMed ID: 2178938
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Letter: Effect of bromocryptine on the fluctuations following dopa therapy. On-off phenomenon in parkinsonian patients].
    Frattola L; Albizzati MG; Spano PF; Trabucchi M
    Nouv Presse Med; 1976 Aug 28-Sep 4; 5(28):1761. PubMed ID: 958891
    [No Abstract]   [Full Text] [Related]  

  • 38. Low-dose bromocriptine in the early phases of Parkinson's disease.
    Tolosa E; Blesa R; Bayes A; Forcadell F
    Clin Neuropharmacol; 1987 Apr; 10(2):168-74. PubMed ID: 3332610
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bromocriptine as initial therapy in elderly parkinsonian patients. The Bromocriptine Multicentre Trial Group.
    Age Ageing; 1990 Jan; 19(1):62-7. PubMed ID: 2180259
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of parkinson's disease with bromocriptine.
    Lieberman A; Kupersmith M; Estey E; Goldstein M
    N Engl J Med; 1976 Dec; 295(25):1400-4. PubMed ID: 989885
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.